Jekrab-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the management of gastroesophageal reflux disease (GERD), acid peptic disorders, and related gastrointestinal conditions. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and gastric discomfort. Rabeprazole, a proton pump inhibitor (PPI), effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief. The synergistic action of these agents provides comprehensive management of acid-related disorders by reducing gastric acidity and enhancing gastrointestinal motility. Jekrab-DSR is indicated for patients experiencing symptoms of GERD, erosive esophagitis, peptic ulcer disease, and functional dyspepsia. It is generally well tolerated; however, caution is advised in patients with known hypersensitivity to either component, and it should be used under medical supervision in those with hepatic or renal impairment. Common adverse effects may include headache, dry mouth, abdominal cramps, or diarrhea. This combination therapy offers an effective approach to improving patient outcomes in acid-related gastrointestinal conditions.